Madhya Pradesh Online Journal

Zika Virus Infection Pipeline Landscape Analysis of 12+ Companies by DelveInsight | Leading Companies – Emergent BioSolutions, Sanofi, and Others

 Breaking News
  • No posts were found

Zika Virus Infection Pipeline Landscape Analysis of 12+ Companies by DelveInsight | Leading Companies – Emergent BioSolutions, Sanofi, and Others

October 03
17:34 2022
Zika Virus Infection Pipeline Landscape Analysis of 12+ Companies by DelveInsight | Leading Companies - Emergent BioSolutions, Sanofi, and Others

DelveInsight’s Zika Virus Infection Pipeline Insight, 2022,” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Zika Virus Infection pipeline landscape.

 

Zika Virus Infection Pipeline landscape is provided which includes the disease overview and Zika Virus Infection treatment guidelines. The assessment part of the Zika Virus Infection pipeline report embraces, in depth Zika Virus Infection commercial assessment and clinical assessment of the pipeline products under development. In the Zika Virus Infection Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Zika Virus Infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Zika Virus Infection Pipeline Report

  • DelveInsight’s Zika Virus Infection Pipeline report depicts a robust space with 12+ active players working to develop 10+ pipeline therapies for various indications.
  • Leading Zika Virus Infection Companies such as Valneva Austria GmbH, Emergent BioSolutions, Themis Bioscience GmbH, ModernaTX Inc, Sanofi, Tychan Pte Ltd., Bharat Biotech International Limited, and are evaluating new Zika Virus Infection pipeline to improve the treatment therapies.
  • The promising Zika Virus Infection therapies in the pipeline in various stages of development includes mRNA 1893, GLS-5700, Tyzivumab, INO-A002, TAK 426, EMX 001, Bemcentinib, Niclosamide, Annexin A5, and many others
  • mRNA-1893 contains an mRNA sequence encoding for the structural proteins of the Zika virus and is designed to cause cells to secrete virus-like particles, mimicking the response of the cell after natural infection. The drug is in Phase II clinical studies for the treatment of Zika Virus Infection. In August 2019, Moderna announced that the US FDA has granted Fast Track designation for its investigational Zika vaccine (mRNA-1893) for the prevention of Zika virus infection in healthy adults.
  • GLS-5700 is a DNA vaccine encoding the pre-membrane and envelop (prM-E) proteins of Zika virus (ZIKV). It is being developed by Geneone life science for Zika Virus Infection and is currently in Phase I stage of development.

 

Request a sample and discover the recent advances in Zika Virus Infection @ Zika Virus Infection Pipeline Outlook

 

The Zika Virus Infection Pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Zika Virus Infection Pipeline Landscape.

 

Zika Virus Infection Overview

Zika fever is a mosquito-borne viral disease caused by Zika virus (ZIKV), consisting of mild fever, rash (mostly maculo-papular), headaches, arthralgia, myalgia, asthenia, and non-purulent conjunctivitis, occurring about two to seven days after the mosquito vector bite. Zika is spread mostly by the bite of an infected Aedes species mosquito (Ae. aegypti and Ae. albopictus). The symptoms typically last for 2-7 days. The diagnosis of the virus is done through a blood test. Zika virus infection during pregnancy can cause infants to be born with microcephaly and other congenital malformations, known as congenital Zika syndrome. Infection with Zika virus is also associated with other complications of pregnancy including preterm birth and miscarriage. Treatment consists of relieving pain, fever, and any other symptom that inconveniences the patient. To prevent dehydration, it is recommended to control the fever, rest, and drink plenty of water.

 

Recent Developmental Activities in Zika Virus Infection Pipeline Report

  • Brazil announced a connection between Zika virus infection and microcephaly in October 2015. The Americas, Africa, and other parts of the world quickly saw outbreaks and transmission evidence. A total of 89 nations and territories have so far reported finding evidence of Zika infection brought on by mosquitoes.
  • The Island of Yap (Federated States of Micronesia) reported the first known outbreak of the Zika virus sickness in 2007. This was followed by a significant Zika virus infection outbreak in 2013 in French Polynesia and other Pacific region nations and territories. Brazil reported a significant rash illness outbreak in March 2015. The outbreak was quickly diagnosed as Zika virus infection, and in July 2015, it was discovered to be linked to Guillain-Barré syndrome.
  • Zika virus outbreaks have been reported in Asia, the Pacific, the Americas, Africa, and the African continent. Rare sporadic human infections were discovered in Africa and Asia during the 1960s and 1980s; these infections were often followed by a minor sickness.

 

Key benefits of the Zika Virus Infection Report

  • The virus that causes the Zika virus infection sickness is mainly spread by Aedes mosquitoes, which bite during the day.
  • Congenital Zika syndrome, which results from zika virus infection during pregnancy, is characterised by the birth of infants with microcephaly and other congenital deformities. Preterm delivery and miscarriage are two more pregnancy problems linked to Zika virus infection.
  • Infection with the Zika virus increases the chance of developing neurologic problems in both adults and children, such as Guillain-Barré syndrome, neuropathy, and myelitis.

 

Zika Virus Infection Pipeline Analysis Report

  • The report provides detailed insights about emerging therapies for the treatment of Zika Virus Infection and the aggregate therapies developed by major pharma companies.
  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Zika Virus Infection Treatment.
  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • The Zika Virus Infection Pipeline Report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Zika Virus Infection market.

The Zika Virus Infection Pipeline Report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Scope of the Zika Virus Infection Pipeline Report

  • Coverage- Global
  • Zika Virus Infection Pipeline Assessment by Phases- Late stage products (Phase III), Mid-stage products (Phase II), Early-stage product (Phase I) along with the details of, Pre-clinical and Discovery stage candidate, Discontinued & Inactive Candidates
  • Zika Virus Infection Pipeline Assessment by Route of Administration- Oral, Parenteral, Intravitreal, Subretinal, Topical, Molecule Type
  • Zika Virus Infection Pipeline Assessment by Molecule Type- Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy, Product Type
  • Zika Virus Infection Companies- Valneva Austria GmbH, Emergent BioSolutions, Themis Bioscience GmbH, ModernaTX Inc, Sanofi, Tychan Pte Ltd., Bharat Biotech International Limited, and many others
  • Zika Virus Infection Therapies- mRNA 1893, GLS-5700, Tyzivumab, INO-A002, TAK 426, EMX 001, Bemcentinib, Niclosamide, Annexin A5, and many others

 

Dive deep into rich insights for Zika Virus Infection Pipeline Assessment, Visit @ Zika Virus Infection Pipeline Therapeutics Assessment

 

Table of content

  1. Introduction
  2. Executive Summary
  3. Zika Virus Infection: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Zika Virus Infection – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug name: Company name
  9. Mid Stage Products (Phase II)
  10. mRNA 1893: Moderna Therapeutics
  11. Early Stage Products (Phase I)
  12. Tyzivumab: Tychan/WuXi Biologics
  13. Preclinical and Discovery Stage Products
  14. EMX 001: Emergex Vaccines
  15. Inactive Products
  16. Zika Virus Infection Key Companies
  17. Zika Virus Infection Key Products
  18. Zika Virus Infection- Unmet Needs
  19. Zika Virus Infection- Market Drivers and Barriers
  20. Zika Virus Infection- Future Perspectives and Conclusion
  21. Zika Virus Infection Analyst Views
  22. Appendix

 

For further information on the Zika Virus Infection Pipeline therapeutics, reach out @ Zika Virus Infection Pipeline Landscape

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/